PMID- 22850601
OWN - NLM
STAT- MEDLINE
DCOM- 20121029
LR  - 20161125
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 92
IP  - 3
DP  - 2012 Sep
TI  - Predictive genetic testing for drug-induced liver injury: considerations of 
      clinical utility.
PG  - 376-80
LID - 10.1038/clpt.2012.107 [doi]
AB  - Genetic predisposition to drug-induced liver injury may be due to variation in 
      both pharmacokinetic and pharmacodynamic pathways. Recent genome-wide association 
      studies have identified, in the human leukocyte antigen (HLA) alleles, strong 
      genetic factors that predispose to liver injury on exposure to any of several 
      drugs. Although the genetic associations have provided mechanistic insights, none 
      has been developed as a predictive test. Further work in this area, in 
      combination with other "-omics" technologies, is needed to develop tests that are 
      both clinically useful and cost-effective.
FAU - Alfirevic, A
AU  - Alfirevic A
AD  - Department of Molecular and Clinical Pharmacology, University of Liverpool, 
      Liverpool, UK.
FAU - Pirmohamed, M
AU  - Pirmohamed M
LA  - eng
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120801
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Alleles
MH  - Chemical and Drug Induced Liver Injury/*genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - *Genetic Testing
MH  - Genome-Wide Association Study
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Sensitivity and Specificity
EDAT- 2012/08/02 06:00
MHDA- 2012/10/30 06:00
CRDT- 2012/08/02 06:00
PHST- 2012/08/02 06:00 [entrez]
PHST- 2012/08/02 06:00 [pubmed]
PHST- 2012/10/30 06:00 [medline]
AID - clpt2012107 [pii]
AID - 10.1038/clpt.2012.107 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2012 Sep;92(3):376-80. doi: 10.1038/clpt.2012.107. Epub 2012 
      Aug 1.